Neura Health raises $11.4M Series A to expand virtual neurology platform
First investment for American Heart Association's Go Red for Women Venture Fund
Neura Health, a virtual neurology clinic focused on improving access to chronic condition care, has secured an $11.4 million Series A funding round to accelerate its national expansion across the United States.
The round was led by the American Heart Association’s Go Red for Women Venture Fund, marking the fund’s first-ever investment. Other participants include Norwest Venture Partners, Koch Disruptive Technologies, Esplanade Ventures, Pear VC, Correlation Ventures, and E12 Ventures. With this raise, Neura has now secured $22 million in total funding.
Tackling a growing access gap
More than 145 million Americans live with a neurological condition, yet the average wait time to see a neurologist stretches four to six months, according to the American Academy of Neurology.
Neura aims to close this gap through a comprehensive digital platform combining virtual visits with neurologists and subspecialists, AI-powered workflows, an integrated patient app, and ongoing education and coaching.
The company is the only tech-enabled model covering the full spectrum of neurology, spanning eight major condition categories: headache and migraine, epilepsy, chronic pain, concussion, stroke recovery, dementia, and undiagnosed neurological symptoms.
“Neura is pioneering a new standard of care for neurological conditions, many of which affect women disproportionately,” said Lisa Suennen, Managing Partner at American Heart Association Ventures.
“Migraine, for example, affects women three times more often than men and those under age 45 who experience migraines with aura have an increased risk of ischemic stroke.”
“By providing faster, more personalized access to care, Neura’s model aligns directly with the Go Red for Women Venture Fund’s purpose to advance heart and brain health for women.”
Expanding into memory care
Earlier this year, Neura moved into memory care to respond to the severe shortage of cognitive neurologists amid the U.S.’s aging population.
There is currently just one cognitive neurologist per one million dementia patients nationwide. The company’s new offering aims to provide earlier diagnoses and ongoing management through its HIPAA-compliant platform.
Demonstrating outcomes
Neura’s approach includes video visits with board-certified neurologists, seven-day appointment availability, AI-driven efficiency tools, integrated symptom tracking, and between-visit care coaching. Unlike text-only or single-condition digital health tools, Neura emphasizes full-spectrum, high-touch neurology care.
The model has already shown measurable impact. Peer-reviewed publications in Headache (2022), Journal of Clinical Medicine (2023), and Current Neurology and Neuroscience Reports (2025) have documented a 73% reduction in emergency and urgent care visits among patients, alongside a 66% increase in global impression of improvement.
Scaling patient reach
To date, Neura has treated more than 43,000 patients and partners with health systems such as Sentara Health. It is also in-network with over 40 health plans, including Aetna, Cigna, Blue Shield of California, Anthem, and Medicare.
CEO and Co-Founder Elizabeth Burstein said her personal experience with chronic nerve pain shaped the company’s mission.
“After struggling to find and manage care for my own chronic nerve pain, I saw firsthand the gaps in care that prevent millions of people like me from finding relief and recovery from chronic neurological conditions,” she said.
“We’ve built Neura Health to bring the highest quality neurological care directly to patients across the country, providing them with empathy, hand-holding, and support as they navigate their care journeys.
“This Series A will help us expand into new condition areas and deepen our collaborations with payers and health systems.”
Data ambitions
Beyond direct care delivery, Neura is also aggregating one of the largest real-world evidence datasets in neurology. By centralizing outcomes, symptoms, and treatment data, the company aims to inform future clinical breakthroughs and attract interest from pharmaceutical partners.